Autologous Cell Concentration Control for Target PRP Platelet Ranges
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing methods struggle to control or manipulate the final product concentrations of platelet-rich plasma (PRP) and bone marrow cell concentrate (BMCC) to a narrow target range, making it difficult to establish dose-response relationships and validate therapeutic effectiveness, and there is a need for systems that prevent premature activation of platelets during separation.
Innovation Solution
A cell concentrating system with a blood separation component, vessels, valves, and flow logic to separate and concentrate blood samples into specific fractions, allowing for the creation of target cell-rich concentrates within a defined concentration range, and includes features to prevent premature platelet activation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If conventional separation methods are used to concentrate platelets and bone marrow cells, then the final product concentration cannot be controlled to a narrow target range, but the ability to establish dose-response relationships and validate therapeutic effectiveness is compromised
Solution Approach 1:
The separation process is divided into multiple sequential centrifugation steps with specific speed parameters. The method uses a series of controlled centrifugation cycles at different speeds (e.g., 1000-2000 g for initial separation, then 2000-4000 g for concentration) to progressively isolate and concentrate target cells, enabling precise control over the final concentration range.
Solution Approach 2:
The method systematically varies centrifugation parameters including speed, duration, and temperature across multiple steps to optimize cell concentration. By adjusting these parameters controllably, the process achieves narrow target concentration ranges (e.g., 1.0-1.5 × 10^6 platelets/μL) while maintaining cell viability and functional integrity.
2Productivity
If conventional separation procedures are used, then platelet activation is premature, but this activates the clotting cascade and compromises therapeutic effectiveness
Solution Approach 1:
Anticoagulant agents are added to the blood sample at the beginning of the separation process to prevent platelet activation before centrifugation. This preliminary protective action ensures that platelets remain in a non-activated state throughout the multi-step separation procedure, preventing premature clotting cascade activation while still enabling efficient cell separation.
Solution Approach 2:
The method uses specialized buffers and anticoagulant solutions as intermediaries to maintain platelets in a stable, non-activated state during handling and centrifugation. These intermediary substances prevent direct platelet activation by external factors while allowing the separation process to proceed efficiently.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enables the production of autologous cell-rich concentrates with precise concentration ranges, facilitating clinical studies and ensuring effective therapeutic outcomes by preventing premature platelet activation.
Implementation Method 1
a centrifuge to separate the blood sample into a red blood cell fraction and a plasma fraction
Data Source
AI summary
An autologous cell concentrating system and method are disclosed. The system has a blood separation component, a first vessel, a second vessel, a first valve, a second valve, and a concentration and flow logic and control component. The concentration and flow logic and control component is configured to: determine a first volume of a target cell-poor fraction in the first vessel to mix with a target cell-rich fraction in the second vessel in order to form a target cell-rich concentrate having a concentration of target cells that is within a target concentration range; and control the second valve to transfer the first volume of the target cell-rich fraction from the first vessel to the second vessel to form the target cell-rich concentrate. The target concentration range is between 1.0 and 1.5×106 target platelets/μL.